EP Patent

EP1064942A1 — Sustained release preparations

Assigned to Astellas Pharma Inc · Expires 2001-01-03 · 25y expired

What this patent protects

Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a sol…

USPTO Abstract

Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.

Drugs covered by this patent

Patent Metadata

Patent number
EP1064942A1
Jurisdiction
EP
Classification
—
Expires
2001-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.